Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C13H11N3O4
Monoisotopic mass
273.074955855
InChI
InChI=1/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
InChI Key
InChIKey=UVSMNLNDYGZFPF-UHFFFAOYNA-N
IUPAC Name
4-amino-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione
Traditional IUPAC Name
pomalidomide
SMILES
NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O
pKa (strongest acidic)
11.59
pKa (Strongest Basic)
1.56
Refractivity
69.03 m3·mol-1
Dược Lực Học :
Pomalidomide is more potent than thalidomide (100-times) and lenalidomide (10-times).
Cơ Chế Tác Dụng :
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells. Furthermore, promalidomide enhances T cell and natural killer (NK) cell-mediated immunity and inhibited the production of pro-inflammatory cytokines, like TNF-alpha or IL-6, by monocytes. The primary target of promalidomide is thought to be the protein cereblon. It binds to this target and inhibits ubiquitin ligase activity. It is also a transcriptional inhibitor of COX2.
Dược Động Học :
▧ Absorption :
Pomalidomide is generally well absorbed. The major circulating component is the parent compound.
Tmax, single oral dose = 2 -3 hours.
When 4 mg of promalidomide is given to patients with multiple myeloma, the steady-state pharmacokinetic parameters are as follows:
AUC(T) = 400 ng.hr/mL;
Cmax = 75 ng/mL.
Promalidomide accumulates following multiple doses.
▧ Volume of Distribution :
Mean apparent volume of distribution (Vd/F), steady-state = 62 - 138 L
▧ Protein binding :
12-44% protein bound. It is not concentration dependent.
▧ Metabolism :
Promalidomide is hepatically metabolized by CYP1A2 and CYP3A4. The metabolites are 26-fold less active than the parent compound. Minor contributions from CYP2C19 and CYP2D6 have been observed in vitro.
▧ Route of Elimination :
When a single oral dose (2mg) is given to healthy subjects, 73% of the dose was eliminated in urine. 15% of the dose was eliminated in feces. 2% and 8% of the dose eliminated unchanged as pomalidomide in urine and feces, respectively.
▧ Half Life :
Healthy subjects = 9.4 hours;
Multiple myeloma patients = 7.5 hours.
▧ Clearance :
Total body clearance = 7-10 L/hour
Độc Tính :
Most common adverse reactions (≥30%) included fatigue and asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upper-respiratory tract infections, back pain and pyrexia.
Chỉ Định :
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Tương Tác Thuốc :
-
Ketoconazole
Strong CYP3A4 inhibitors may increase levels of pomalidomide. Concomitant therapy should be avoided.
-
Rifampicin
Strong CYP3A4 inducers may decrease levels of pomalidomide. Concomitant therapy should be avoided.
Liều Lượng & Cách Dùng :
Capsule - Oral - 1 mg, 2 mg, 3 mg, 4 mg
Tài Liệu Tham Khảo Thêm
National Drug Code Directory